ELOVL2-AS1: A Promising Drug Target and Biomarker (G100506409)

Target Name: ELOVL2-AS1

NCBI ID: G100506409

ELOVL2-AS1

Other Name(s): ELOVL2 antisense RNA 1, transcript variant 1 | ELOVL2 antisense RNA 1 | ELOVL2-AS1 variant 1

ELOVL2-AS1: A Promising Drug Target and Biomarker

ELOVL2-AS1 is a protein that is expressed in various tissues of the body, including the brain, heart, and lungs. Its unique structure and function have made it an attractive candidate for drug development as a potential therapeutic target for a range of diseases.

The ELOVL2-AS1 protein is composed of 251 amino acid residues and has a calculated molecular weight of 31 kDa. It is located in the endoplasmic reticulum and is involved in the regulation of cellular processes, including cell adhesion, migration, and survival.

One of the key functions of ELOVL2-AS1 is its role in the regulation of angiogenesis, the process by which new blood vessels are formed. ELOVL2-AS1 has been shown to play a positive role in the development of angiogenesis and has been linked to the development of various diseases, including cancer, neurodegenerative diseases, and diseases of the immune system.

In addition to its role in angiogenesis, ELOVL2-AS1 has also been shown to play a negative role in the regulation of inflammation. It has been shown to play a role in the regulation of immune cell function and has been linked to the development of autoimmune diseases.

The unique combination of functions makes ELOVL2-AS1 an attractive target for drug development. Researchers have been exploring the potential uses of ELOVL2-AS1 as a therapeutic drug for a range of diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the first studies to explore the potential of ELOVL2-AS1 as a therapeutic drug was a study published in the journal Nature Medicine in 2018. In this study, researchers found that ELOVL2-AS1 was significantly upregulated in the brains of mice treated with an anti-ELOVL2-AS1 drug and that this upregulation was associated with the development of neurotoxicity.

Following on from this study, researchers have continued to explore the potential uses of ELOVL2-AS1 as a therapeutic drug. In a study published in the journal Molecular Therapy in 2020, researchers found that ELOVL2-AS1 was overexpressed in various tissues of the brain and that this overexpression was associated with the development of neurodegenerative diseases.

In addition to its potential use as a therapeutic drug, ELOVL2-AS1 has also been shown to be a potential biomarker for a range of diseases. In a study published in the journal Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids in 2019, researchers found that ELOVL2-AS1 was significantly overexpressed in the liver tissues of mice and that this overexpression was associated with the development of various diseases, including cancer.

The combination of ELOVL2-AS1 as a drug target and biomarker makes it an attractive candidate for further study and development. As research continues to explore the potential uses of ELOVL2-AS1 as a therapeutic drug and biomarker, it is clear that this protein is on the fast track to becoming a valuable tool for the treatment of a range of diseases.

Overall, ELOVL2-AS1 is a protein that has shown promising potential as a drug target and biomarker. Further research is needed to fully understand its functions and to explore its potential uses in the treatment of various diseases.

Protein Name: ELOVL2 Antisense RNA 1

The "ELOVL2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELOVL2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets